The goal of antimicrobial prescription is to achieve effective drug concentrations. Standard antimicrobial dosing regimens are based on research performed often decades ago and for the most part with patients who were not critically ill. More recent insights into antibiotic activity (e.g. the importance of high peak/MIC ratios for aminoglycosides and time above MIC for β-lactam antibiotics), drug pharmacokinetics (e.g. increased volume of distribution and altered clearances) and the pathogenesis of sepsis (e.g. third space losses and altered creatinine clearances) have made re-evaluation of dosing regimens necessary for the critically ill.
The goal of antimicrobial prescription is to achieve effective active drug concentrations that result in clinical cure while avoiding drug-associated toxicity [1] [2] [3] [4] [5] [6] . Effective drug concentrations are said to be attained when levels are maintained either above the minimum inhibitory concentration (MIC) for the infecting organism or at the minimum bactericidal concentration (MBC) for variable periods of the dosing interval. Standard antimicrobial dosing regimens are based on research from animal models 1, 4, 5, 7 . More recent insights into antibiotic activity, drug pharmacokinetics and the pathogenesis of sepsis have cast doubt on these guidelines and caution is advised in extrapolating from animal models to critically ill human patients 4, 5, [8] [9] [10] [11] .
The inflammatory response associated with sepsis involves the release of cytokines and other mediators, endothelial damage and changes in capillary permeability 12, 13 . The acute phase response results in a rapid decrease in serum albumin levels. Included in the overall response are fluid shifts and third space losses resulting in large extravascular, interstitial fluid accumulation 12, 13 . Until haemodynamic collapse supervenes, the cardiac output in sepsis is high 14 .
Therefore, the pathophysiological changes of sepsis result in increased creatinine clearance unless these effects are offset by ensuing renal and/or hepatic impairment. Renal and hepatic impairment result in prolongation of drug half-life, decreased clearance and drug accumulation 6 . Thus, antimicrobial prescribing in sepsis must take into account the opposing effects of increased drug clearance and increased volumes of distribution resulting in low serum drug concentrations versus organ dysfunction resulting in high serum drug concentrations. At different stages of the disease process, the antibiotic requirements of the critically ill patient may be similar, less or greater than those of the conventional ward patient (Figure 1 ).
If severe renal dysfunction occurs (GFR <15 ml/min), renal replacement therapy (RRT) is usually instituted. In Australia and increasingly world-wide, such RRT is typically continuous (CRRT). CRRT has significant repercussions on the dosing of antibiotics because it increases their clearance and may lead to their adsorption to the filter. The principles of drug removal during RRT need to be clearly understood in order to avoid under-or overdosing of antimicrobials in the intensive care setting. Although we address renal replacement therapy (RRT) in more detail towards the end of this review, specific points about each antibiotic class are stressed in the appropriate antibiotic section.
This article provides principles for more effective and appropriate antibiotic dosing in the critically ill based on the pharmacokinetic and pharmacodynamic principles of the main antibiotic groups (aminoglycosides, glycopeptides, and quinolones) and knowledge of the pathophysiology of severe sepsis.
APPLIED CLINICAL PHARMACOLOGY
Understanding the relationship between the pharmacodynamic and pharmacokinetic properties of an antibiotic helps to determine the optimal dosage regimen and to predict which pharmacokinetic parameter should correlate best with clinical efficacy. Parameters to consider are peak drug concentration, time above the minimum inhibitory concentration (MIC), the area under the serum concentration time curve (AUC) and the area under the inhibitory curve (AUC/MIC or AUIC). Pharmacodynamics of antibiotics relate to the timecourse of drug activity and the mode of action on bacteria ("kill characteristics") and includes the postantibiotic effect (PAE) and other persisting drug effects.
Aminoglycosides
The kill characteristic of the aminoglycosides is concentration-dependent 1, 2, 7, [15] [16] [17] [18] [19] . Experimentally, a high peak concentration of an aminoglycoside antibiotic provides a better, faster killing effect on standard bacterial inocula. Moore et al 20 , in a retrospective study analysing clinical outcome after aminoglycoside administration, demonstrated quite unequivocally that a high peak concentration of aminoglycoside relative to the MIC for the infecting organism was a major determinant of the clinical response. However, there has been continued reticence to the use of high dose aminoglycosides because of the narrow therapeutic index. However, there is now much evidence to show that administering the daily dose of aminogylcoside as a single dose is associated with less nephro-and ototoxicity than the same dose given in small, multiple doses [21] [22] [23] [24] [25] [26] [27] . It is therefore deduced that the troughs-or more specifically the AUC-are more to blame for the adverse renal and ototoxic effects of these drugs [21] [22] [23] [24] [25] [26] [27] . When given intravenously, "peak" aminoglycoside levels are achieved at about 30 minutes. The plasma half-life (t½) of aminoglycosides varies with renal function, but with normal renal function both the naturally occurring and semi-synthetic agents have a t½ of between two and three hours 28 . From a practical point of view, six to eight hours (3-4 xt½) after a dose the serum levels of aminoglycoside will be very low in patients with normal renal function.
All aminoglycosides exhibit a significant postantibiotic effect (PAE) 1, 7, [15] [16] [17] [18] 20 . This refers to the continued suppression of bacterial growth despite zero concentration of antibiotic as measured by standard assays. The duration of this effect is variable (between two and eight hours) and is dependent on several factors, the most important of which is the preceding peak concentration of aminoglycoside, i.e. PAE is concentration dependent 1 . This phenomenon allows drug concentration to fall significantly below MIC of the pathogen without allowing regrowth of bacteria and hence not compromising antibacterial efficacy. The phenomenon of PAE is much more prevalent with aminoglycosides than other antibiotics and more pronounced for Gram negative bacilli than with other bacteria. The PAE is not explained by the serum half-life effects of aminoglycosides.
The volume of distribution (Vd) of aminoglycosides is between 0.2 and 0.3 l/kg in patients with normal renal function. This means that these drugs are almost exclusively maintained in the extracellular space due to minimal protein binding 6, 29 . Aminoglycosides are excreted unchanged almost entirely by glomerular filtration 6 resulting in high renal and urinary concentrations of drug.
Patient variability in peak serum concentrations is a problem in aminoglycoside dosing 6, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . Various factors such as inflammatory processes, vascular permeability, fluid extravasation and "third space" losses, affect the volume of distribution of drug 12, 13, 40 . The Vd of aminoglycosides has been shown to increase with patient sickness severity, measured by APACHE II score 41 . Importantly, the critically ill patient with a high APACHE II score and normal renal function will not only have lower trough levels, but also lower peak levels compared with a patient who has a lower APACHE II score. The effect of sickness severity on aminoglycoside levels, resulting in variation in the volume of distribution in an individual patient during the course of therapy, may explain, at least in part, the wide variability of dosages needed to achieve therapeutic levels as reported in published studies [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] .
Optimization of dosage schedules, reducing the toxicity, yet retaining a high kill rate, has been the subject of at least 50 studies, and almost a dozen meta-analyses [42] [43] [44] . Many trials set out to obtain high peak levels (at one hour) and a four-hour antibioticfree period thought to reduce toxicity 45 . There is still significant antibacterial action during the antibioticfree period, explained by the post antibiotic effect (PAE) 46 . Furthermore, when antibiotic combinations are prescribed, the synergism of aminoglycosides and β-lactams offsets any reduction in therapeutic effect occurring as a result of low drug levels of aminoglycoside.
Understanding the pharmacokinetic and pharma-codynamic properties of aminoglycosides, (i) high, widely spaced doses causing less toxicity than smaller more frequent doses; (ii) high doses producing better kill curves; and (iii) the PAE, led to the concept of single daily dosing for aminoglycoside antibiotics 47, 48 . It has now been shown in prospective human clinical trials [49] [50] [51] [52] that this recommendation is valid, i.e. large, single, daily doses of aminoglycosides produce a better clinical outcome and less toxicity.
In designing the once daily dosing regimen of aminoglycosides, the dosage was calculated by multiplying the eight hourly dose (1-1.5 mg/kg) by three, thus prescribing the same total dose given in a 24 hour period. This technique is still used successfully by a large number of centres. However, the largest single series reported by Nicolau et al 45 varied the dosing interval according to the creatinine clearance. A single daily dose of 7 mg/kg was administered if the creatinine clearance was ≥60 ml/min. With lower creatinine clearances (59-40 ml/min) the same dose was suggested at an interval of 36 hours and with even lower clearances (39-20 ml/min), the dosing interval increased to 48 hours. This study used higher doses than previously suggested, aiming for a greater peak/MIC ratio. There was no apparent reduction in efficacy but there was a decrease in toxicity compared with a historical control at the same institution.
Recently the results of many smaller trials have been amassed and subjected to meta-analysis by a number of different groups. In one meta-analysis involving over 2000 patients, once daily administration was found to be more efficacious (odds ratio 1.47) 53 . Whilst other meta-analyses have been less optimistic as to the increased efficacy, they have all shown a reduction in toxicity and, at least, no reduction in efficacy [42] [43] [44] . These benefits are significant: reduced toxicity, higher peak/MIC ratios, further prolonged PAE and reduced ancillary costs largely related to simplifying administration.
The need for RRT has profound effects on aminoglycoside dosing. Protein binding of aminoglycosides is limited. The sieving coefficient (S) for convection or dialysis is approximately 0.9 and CRRT clearance is increased by some filter adsorption 54, 55 . Therefore, correct dosage requires knowledge of the Vd and of the effluent flow rate during the dosing interval.
β-lactam Antibiotics
In vivo animal experiments have demonstrated that the kill characteristics of β-lactam antibiotics differ significantly from those of aminoglycosides. β-lactams have a slow continuous kill characteristic.
Bacterial killing, therefore, is almost entirely related to the time for which levels in tissue and plasma exceed a certain threshold. β-lactam antibiotics lack a significant post-antibiotic effect, particularly against Gram negative organisms. Furthermore, once the concentration of the antibiotic falls too low, any bacteria remaining in the inoculum proliferate almost immediately 1, 2, 7, [15] [16] [17] [18] [19] 56 . A study in rabbits with experimental aortic endocarditis due to P. aeruginosa investigated development of resistance to cefpirome and ceftazidime 57 . This study showed that resistance developed only in animals whose plasma concentrations were above the MIC for less than half the dosing interval. Roosendaal et al 16 , using a rat model, reported better results in treating sepsis with continuous infusions of ceftazidime.
Studies have consistently shown that, for β-lactam antibiotics, the best correlate for therapeutic efficacy is the percentage of the dosage interval for which drug concentrations remain above the MIC for the infecting organism (T>MIC) 3 . It has been proposed that, in the absence of any post-antibiotic effect, the plasma concentration of a β-lactam antibiotic should exceed the MIC for the respective organism for 90%-100% of the dosing interval 3 . Dosing regimens of β-lactam antibiotics are currently undergoing re-evaluation to ascertain the optimal length of time for which drug levels should exceed the MIC [3] [4] [5] 56, 58, 59 .
Furthermore, experimental studies have demonstrated that maximum killing of bacteria occurs at four to five times MIC, although levels higher than this may not produce added efficacy. Mouton and den Hollander, in an in vitro pharmacokinetic model using resistant pseudomonas strains, demonstrated the need for sustained ceftazidime concentrations above four to five times MIC 56 . When antibiotic concentrations fell below this threshold in these models bacterial growth resumed immediately. The necessity for a relatively high threshold concentration is supported by a recent in vitro study of isolates obtained from patients with cystic fibrosis 60 . Some researchers propose that concentrations of any β-lactam antibiotic should be maintained above four to five times the MIC for long periods 7, 15, 16 .
In instances where the recommended time above MIC is for an extended period of the dosing interval, the logical conclusion is to administer the drug by continuous infusion. Pharmacokinetic-pharmacodynamic modelling to determine the optimal dosage regimen, using different bacterial growth models, supports a regimen with a loading dose followed by a continuous infusion, provided that concentrations greater than the required threshold are achieved 59 . Such a regimen maintains trough levels and elimi-nates high peak serum concentrations that confer no additional therapeutic benefit. Numerous studies have compared the use of continuous infusion for β-lactam administration with intermittent boluses, showing comparable therapeutic efficacy and, with the former, a reduction in the total dose of drug given 58, [61] [62] [63] [64] [65] .
As with the aminoglycosides, it has become increasingly apparent that the pharmacokinetics of the β-lactam antibiotics in the critically ill patient are different from those in the ward patient 8, 66 . Many studies evaluating serum concentrations of antibiotics in the critically ill have demonstrated lower levels than expected [8] [9] [10] 17, 30, 32, 33, [66] [67] [68] [69] [70] [71] [72] . Drug levels may be low in the early phase of sepsis with increased cardiac output and normal renal function resulting in increased drug clearance. However, once either renal impairment sets in or pre-renal blood flow falls, as with myocardial depression, drug clearance decreases and serum drug concentrations will be maintained at higher levels. This trend has been demonstrated in several studies evaluating β-lactam antibiotics 9,10,61-65,71,72 . One inclusion criterion common to many of these studies was normal serum creatinine levels, i.e. relatively normal renal function. Creatinine clearance measured during these studies was found to be unexpectedly high, presumably due to increased cardiac output and glomerular filtration occurring in sepsis as described above. In two of these studies it has been shown that clearances of cefepime and, more recently, cefpirome are linearly related to creatinine clearance 9, 10 . In-house comparisons made between cefepime and cefpirome demonstrate the two drugs are cleared in a similar fashion in intensive care patients (in-house data-submitted). Any differences in drug clearance can largely be attributed to differences in creatinine clearance. Despite normal plasma creatinine concentrations in many patients, antibiotic plasma concentrations were less than the susceptible cutoff value of 4 mg/l. A third of patients had creatinine clearances >144 ml/min (20% higher than an expected maximum of 120 ml/min). Only creatinine clearance was an independent predictor of antibiotic clearance. Time greater than MIC was only predicted by creatinine clearance and serum levels of these antibiotics would be low when using standard dosing regimens in septic patients 9, 10 . In clinical terms, this means that in septic patients with a high creatinine clearance, serum levels of those antibiotics will be low when using standard dosing regimens.
Studies have also shown that bolus dosing of cephalosporins 9,10,71,72 produces peaks that are unnecessarily high with troughs often below MIC for much of the dosing interval. An improved antibiotic profile is obtained with either more frequent dosing 3, 9 or continuous infusions 3, 9, 58, 59, [61] [62] [63] [64] [65] [66] 71, 72 .
RRT also affects β-lactam drugs which have highly variable S values according to the amount of protein binding. Drugs like ceftriaxone have limited removal while other drugs such as ampicillin or ceftazidime have clearance rates close to that of aminoglycosides. Clinicians should refer to tables of S values to help optimize prescribing practice with these agents in patients receiving CRRT 73, 74 .
Carbapenems
Theoretically the carbapenems should demonstrate kill characteristics similar to other β-lactam antibiotics. However, there are significant differences. For example, in contrast to other more conventional β-lactam antibiotics, the carbapenems exhibit some PAE effects 75 .
With reference to dosage schedules of the carbapenems, studies evaluating meropenem have shown this drug to be as effective by continuous infusion as by intermittent dosing [76] [77] [78] . Continuous infusion regimens described offer a significant cost saving as the total daily dose by infusion is less than that given by intermittent bolus doses 76, 79 . Davies and coworkers have suggested that the administration of meropenem by continuous infusion may reduce the incidence of resistant organisms 79 . Meropenem exhibits an inhibitory effect on bacteria when the concentrations are maintained above the MIC for approximately 33-40% of the dosing interval 78 .
Although pharmacokinetic studies evaluating meropenem in the critically ill are limited, the available evidence suggests that in septic patients the Vd for meropenem is increased and peak levels are decreased compared with healthy volunteers 78. However, these findings may have been influenced by fluid shifts following surgery in patients with intraabdominal infection. Renal impairment increases the drug half-life and consequently dosing schedules that are half the standard dose are recommended in patients with creatinine clearance <10 ml/min.
The clearance of imipenem/cilastatin and meropenem during CRRT have been studied 80, 81 . Imipenem and cilastatin have different S values, thus a given dose of drug that avoids accumulation of imipenem results in accumulation of cilastin, exposing the patient to the risk of seizures. For this reason, meropenem is the preferred carbapenem in these patients. The S value for meropenem is close to 1, thus its clearance is essentially the same as the effluent rate. Dosing has to be adjusted accordingly.
Vancomycin (as Representative of the Glycopeptides)
Vancomycin has pharmacodynamic-pharmacokinetic properties in common with both aminoglycoside and β-lactam antibiotics.
Vancomycin, like the aminoglycosides, is poorly protein bound and distributes into the extravascular space. Conditions such as sepsis and burns associated with increased capillary permeability and increased extracellular water, demand higher doses of vancomycin 12, 13 . Vancomycin in the intensive care setting has also been demonstrated to have, not unexpectedly, an increased Vd in infants with the systemic inflammatory response syndrome 11 . The same study also demonstrated a significantly lower peak serum concentration for a given dosage based on weight on day 2 of therapy compared with the same dose on day 8. To achieve therapeutic levels in septic patients with an increased volume of distribution, doses of vancomycin may need to be higher than those generally recommended (>40 mg/kg/day).
However, there is conflicting evidence to suggest that lower levels of vancomycin than are recommended currently may be as effective and limit drug accumulation 82, 83 . The available data suggest that the bactericidal activity of vancomycin is concentrationindependent 82, 84 . Optimal vancomycin therapy may be with sustained therapeutic concentrations without high peaks 82 . Studies have evaluated vancomycin administered by continuous infusion and demonstrated apparent resolution of infection [85] [86] [87] . A larger, multi-centred, randomized, but still underpowered trial, comparing intermittent vs continuous infusion vancomycin demonstrated comparable efficacy and tolerance 88 . None of these studies has been large enough to provide definitive answers and further evaluation is warranted. Vancomycin given by continuous infusion may also reduce the emergence of resistant bacterial strains 79 .
Furthermore, vancomycin induces a PAE and a post-antibiotic sub-MIC effect (PA-SME). These combined effects suggest that bacterial regrowth will not occur for prolonged periods following a fall in drug concentrations to levels below the MIC 82 .
Vancomycin is profoundly affected by CRRT as discussed below. Teicoplanin, on the other hand, is minimally affected by CRRT with an S value of 0.1 so dosage would be very similar to that given in the absence of renal replacement therapy.
Ciprofloxacin (as Representative of the Fluoroquinolones)
Ciprofloxacin has a combination of both concentration-dependent and time-dependent kill characteristics [89] [90] [91] [92] . A suggested "target" parameter for a good clinical bactericidal effect is a peak concentration (C max ) up to eight times the MIC 89 . Quinolones exhibit a PAE [90] [91] [92] [93] [94] . Therefore peak concentrations alone may not correspond with optimal in vivo killing. It has been shown experimentally that the best correlation of ciprofloxacin efficiency is a combination of peak concentrations and times above MIC, i.e. the whole area under the serum concentration-time curve (AUC). The AUC/MIC ratio (which is equivalent to the area under inhibitory curve AUIC) >125 for Gram negative and >30 for Gram positive organisms has been shown to correlate with better clinical outcomes 89, 91, [95] [96] [97] .
The optimal intravenous dose of ciprofloxacin is unknown and various theoretical suggestions for dosing regimens have been suggested 98 . High peak serum concentration/MIC ratios and the area under the inhibitory curve >100-150 aid bacterial killing and have been suggested as surrogate goals for quinolone dosing schedules [89] [90] [91] [92] [95] [96] [97] . The induction of any PAE would enhance the kill characteristics of quinolones.
There is general concern about the emergence of resistant bacteria related to inappropriately low doses of ciprofloxacin particularly Enterococci, Pseudomonas species and methicillin-resistant Staphylococcus sp [99] [100] [101] . Organisms are usually regarded as sensitive to ciprofloxacin if the corresponding MIC is less than 1 mg/l and resistant if the MIC is greater than 4 mg/l 102 .
Recently published data evaluated ciprofloxacin 400 mg given eight hourly to critically ill septic 139 ANTIBIOTIC DOSING IN THE CRITICALLY ILL patients with normal renal function 103 . This dosage was found to be safe and to provide not only high C max but also good AUC levels. A large multi-centred clinical trial had documented efficacy of this dosage regimen with very few side-effects 104 .
Additional data evaluating ciprofloxacin (in-house data-submitted for publication) will soon be available showing that, in contrast to vancomycin and aminoglycosides, the Vd for ciprofloxacin does not significantly change with fluid shifts, nor does it change over time. It is postulated that this is because ciprofloxacin has better tissue penetration than vancomycin and aminoglycosides. The latter two distribute into the extravascular compartment but not so well throughout the "total body water" compartment. Ciprofloxacin, however, is distributed throughout the total body water compartment and this remains relatively constant during disease processes.
Ciprofloxacin, ofloxacin and other quinolones have S values of 0.6 to 0.7. Because of their S values these agents require some dose adjustments according to the desired target levels, the patient's Vd and the effluent rate of the CRRT technique being applied.
RENAL REPLACEMENT THERAPY AND ANTIMICROBIALS 73, 74, [105] [106] [107] The serum levels of all antimicrobials are affected by the use of RRT, whether in the form of intermittent haemodialysis (IHD) or continuous haemofiltration (CRRT). If IHD is applied, several antibiotics are effectively removed and require repeat dosing after the IHD session 74 . Other antibiotics are minimally removed (ciprofloxacin) and require readjustment for the overall creatinine clearance but no repeat dosing after IHD. Vancomycin is not removed at all if standard cellulose or low-flux biosynthetic membranes are used. However, if high-flux biosynthetic membranes are used and especially if some convective clearance is applied (intermittent haemodiafiltration or intermittent haemofiltration), then vancomycin clearance can be significant and adjusted re-dosing may be necessary 73 . Therefore, if working in a unit where such intermittent therapy is used, the intensive care physician needs to understand these issues and become familiar with the technical characteristics of the IHD applied in that institution.
As CRRT is now more commonly applied to the care of critically ill patients with acute renal failure in many centres, some of the basic principles of drug clearance during CRRT need to be understood. First, only the free drug is available for clearance. The protein-bound portion cannot be removed during CRRT. Second, only water-soluble drugs can be removed.
Agents that are lipid soluble such as liposomal amphotericin cannot. Third, essentially all antimicrobials are small enough to pass through the highflux membranes typically used for CRRT and, in their free form, are available for removal. Fourth, some antibiotics such as aminoglycosides display the phenomenon of membrane binding especially with polyacrylonitrile membranes. Such membrane binding can lead to the removal of 20 to 30 mg 54, 74 . Finally, the mode of solute clearance during CRRT-diffusion as in continuous veno-venous haemodialysis (CVVHD) or convection as in continuous venovenous haemofiltration (CVVH)-modifies the clearance of larger antibiotics, such as the glycopeptides. Convective clearance in CVVH is more effective in removing middle molecules and therefore increases the clearance of drugs such as vancomycin.
In order to understand the effect that CRRT can have on antibiotic therapy, one needs to introduce some fundamental concepts of drug clearance during artificial renal replacement therapies. The first is that of the sieving coefficient (S), which is a measure of how well a solute moves across the membrane in a convective mode. If movement is complete, as is the case for urea, S=1. If there is no movement, as is the case for albumin, S=0. For a given solute the sieving coefficient is given by the following equation:
S=UFc/Pc
where Pc is the average plasma concentration of the solute in the filter and UFc its concentration in the ultrafiltrate. Pc is then equal to the plasma concentration at filter inlet plus the concentration at filter outlet divided by two.
Clearance can then be simply calculated as Cl=S xUF rate in ml/min If the therapy is diffusive, the equivalent of S is the so-called dialysate saturation (Sd). In most clinical circumstances (with the exception of vancomycin), S=Sd. Therefore, one needs to know the S for a given drug, the UF rate or dialysate flow rate or in mixed therapies, the ultradiafiltrate flow rate, and one can calculate drug clearance during CRRT. Tables are available with S values for drugs used in ICU 106 . For example, if one is operating a CVVH system at 2 l/hr (33.3 ml/min) and assessment of vancomycin clearance is necessary, one can use the S for vancomycin, which is approximately 0.7 (it varies slightly depending on protein binding):
Cl vanc=0.7x33.3 ml/min Thus a vancomycin clearance of approximately 23 ml/min can be expected. The t½ for vancomycin 140 can then be calculated if one knows the Vd. Practically, one can give an initial dose of 1g of vancomycin and measure the peak level to calculate the Vd. If the patient is anuric, and the peak level is 25 mg/l, then, in this patient t½ (min)=0.693 x 40,000 ml/23 ml per minute, which is 1205 minutes, i.e. 20 hours.
If one is operating in CVVHD (diffusive mode), Sd is about 30-40% less than S 108 , thus clearance is decreased by the same amount. Although membrane function and therefore S is dynamic and dependent on the age of the membrane and the filtration fraction (UF flow rate/plasma flow rate) (Figures 3 and  4) , the above approximations are sufficient for safe and effective drug dosing in the clinical environment.
CONCLUSION
Antibiotic regimens have hitherto been derived from trials on patients who are not critically ill. In order to optimize antibiotic regimens in the ICU, the pathophysiological effects of the systemic inflammatory response syndrome need consideration, in conjunction with awareness of the different kill characteristics of the various antibiotic classes.
Fluid shifts between different body compartments, fluid resuscitation and the effects of surgery all impact on Vd and C max in a variable and largely unpredictable manner. The tissue penetration characteristics of antibiotics is also a consideration. Aminoglycosides and vancomycin penetrate extracellular fluid compartments primarily, whereas the β-lactams and quinolones better penetrate intracellular compartments. However, it is reasonable to assume that in the early stages of sepsis when patients often have increased cardiac output and increased renal blood flow, increased antibiotic dosages are required. Later in the disease process, organ dysfunction may necessitate re-evaluation and reduction of dosing requirements. Drug washout from blood loss and peritoneal lavage during surgery may cloud the issue further. Awareness of the kill characteristics of the antibiotic in question helps determine the optimum mode of administration, as in single daily dosing for aminoglycosides or by continuous infusion for β-lactams and possibly vancomycin. Information on dosing schedules in critically ill patients undergoing continuous renal replacement therapy is limited and warrants further investigation.
Finally, a recent, albeit small, study 109 using microdialysis techniques showed very low concentrations of piperacillin in tissues. This concept (and technique) 110 may require us to re-evaluate all antibiotic regimens.
Further studies with larger numbers of patients are needed to describe doses and regimens that are more appropriate for use in the critically ill, and which may differ significantly from more common antibiotic prescribing practices. However, with the information currently available, including recent insights into the appropriate therapeutic targets, and understanding of the fundamentals of pharmacokinetics, pharmacodynamics and of drug clearance during CRRT, the intensive care clinician can safely and effectively prescribe almost all antimicrobials to critically ill patients with life-threatening infections. 
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Sieving coefficient FIGURE 4: Graphic representation of the effect of filtration fraction on sieving coefficient (S). Given a blood flow of 100 ml/min (plasma flow of approximately 70 ml/min), an increase in ultrafiltration rate from 14 ml/min to 28 ml/min will decrease the S for drugs like vancomycin by approximately 30%.
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